-
Atosiban Acetate
CAS:90779-69-4
-
Edotreotide
CAS:204318-14-9
-
Difelikefalin*
CAS:1024828-77-0
-
Pegcetacoplan*
CAS:2019171-69-6
-
Fulvestrant
CAS:129453-61-8
-
Oxytocin
CAS:50-56-6
Certification:Japanese DMF
-
Retatrutide*
CAS:2381089-83-2
-
Teriparatide
CAS:52232-67-4
-
Setmelanotide*
CAS:920014-72-8
-
Teduglutide
CAS:287714-30-1
-
Atorvastatin Calcium
CAS:344423-98-9
-
Alogliptin Benzoate*
CAS:850649-62-6
Certification:CEP/COS
Product Pipeline
-
R&D
-
Pilot
-
Validation
-
DMF file
-
Commercial
-
Peptides
-
Small Molecules
-
Oligonucleotides
-
Bivalirudin
-
Cetrorelix Acetate
-
Eptifibatide
-
Lanreotide Acetate
-
Octreotide Acetate
-
Thymalfasin
-
Atosiban Acetate
-
Desmopressin Acetate
-
Liraglutide*
-
Semaglutide*
-
Tirzepatide*
-
Edotreotide
-
Oxytocin
-
Retatrutide*
-
Teriparatide
-
Difelikefalin*
-
Pegcetacoplan*
-
Setmelanotide*
-
Teduglutide
-
Ziconotide
-
Atorvastatin Calcium
-
Fulvestrant
-
Oseltamivir Phosphate
-
Agomelatine
-
Alogliptin Benzoate*
-
Epalrestat
-
Sodium Picosulfate
-
Sulindac
-
Risdiplam*
-
Dydrogesterone
-
Elacestrant*
-
Ezetimibe
-
Rimegepant*
-
Roxadustat*
-
Ubrogepant*
-
Nusinersen*
-
CPG 1018
-
CPG 2007
-
CPG 2216
-
Givosiran*
-
Inclisiran*
-
Patisiran*
-
Vutrisiran*
*Disclaimer: Due to the limitation of patent protection, commercial production and sales will not be carried out for the time being, and will only be used for scientific research and administrative approval.